GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioGend Therapeutics Co Ltd (ROCO:6733) » Definitions » Additional Paid-In Capital

BioGend Therapeutics Co (ROCO:6733) Additional Paid-In Capital : NT$-0.2 Mil(As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BioGend Therapeutics Co Additional Paid-In Capital?


BioGend Therapeutics Co's quarterly additional paid-in capital stayed the same from Dec. 2023 (NT$0.0 Mil) to Mar. 2024 (NT$0.0 Mil) and stayed the same from Mar. 2024 (NT$0.0 Mil) to Jun. 2024 (NT$-0.2 Mil).

BioGend Therapeutics Co's annual additional paid-in capital declined from Dec. 2021 (NT$212.8 Mil) to Dec. 2022 (NT$0.0 Mil) but then stayed the same from Dec. 2022 (NT$0.0 Mil) to Dec. 2023 (NT$0.0 Mil).


BioGend Therapeutics Co Additional Paid-In Capital Historical Data

The historical data trend for BioGend Therapeutics Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGend Therapeutics Co Additional Paid-In Capital Chart

BioGend Therapeutics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 301.11 160.90 212.85 - -

BioGend Therapeutics Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.15

BioGend Therapeutics Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

BioGend Therapeutics Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BioGend Therapeutics Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGend Therapeutics Co Business Description

Traded in Other Exchanges
N/A
Address
4th Floor, Number 3, Park Street, Nangang District, Taipei, TWN, 115
BioGend Therapeutics Co Ltd is a Taiwan based company involved in developing regenerative bio-orthopaedic medicine to advance the clinical science of maintaining healthy joints in skeletal system. The Company is primarily engaged in the research and development of bone medical device related products. Its products under development include Big-001, Big-006 and Big-009.

BioGend Therapeutics Co Headlines

No Headlines